CTOs on the Move

Cerecin

www.cerecin.com

 
Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin`s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of medium-chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world`s leading manufacturers of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cerecin.com
  • 44 Cook Street Suite 100-71
    Denver, CO USA 80206
  • Phone: 303.999.3700

Executives

Name Title Contact Details

Similar Companies

SK pharmteco

Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Koreas SK Group.

Tropical Looks Day Spa

Tropical Looks Day Spa is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integral BioSystems

To transform research concepts from the lab to clinic-ready products.Integral BioSystems was founded by drug development experts with many years of combined expertise in pharmaceutics and the development of drug products. The company is based in the greater Boston area.

The KPC Group

The KPC Group is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.